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OBJECTIVE — C-reactiveprotein(CRP)iscloselyassociatedwithobesityandcardiovascular
disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed
antidiabetic agents have different effects on CRP; however, the long-term effects of those agents
are unknown.
RESEARCH DESIGN AND METHODS — In A Diabetes Outcome Progression Trial
(ADOPT),weexaminedthelong-termeffectsofrosiglitazone,glyburide,andmetforminonCRP
and the relationship among CRP, weight, and glycemic variables in 904 subjects over 4 years.
RESULTS — BaselineCRPwassigniﬁcantlycorrelatedwithhomeostasismodelassessmentof
insulin resistance (HOMA-IR), A1C, BMI, waist circumference, and waist-to-hip ratio. CRP
reductionwasgreaterintherosiglitazonegroupby47.6%relativetoglyburideandby30.5%
relative to metformin at 48 months. Mean weight gain from baseline (at 48 months) was 5.6 kg
withrosiglitazone,1.8kgwithglyburide,and2.8kgwithmetformin.ThechangeinCRPfrom
baseline to 12 months was correlated positively with change in BMI in glyburide (r  0.18) and
metformin(r0.20)groupsbutnotintherosiglitazone(r0.05,NS)group.However,there
wasnolongerasigniﬁcantcorrelationbetweenchangeinCRPandchangeinHOMA-IR,A1C,or
waist-to-hip ratio in any of the three treatment groups.
CONCLUSIONS — Rosiglitazone treatment was associated with durable reductions in CRP
independent of changes in insulin sensitivity, A1C, and weight gain. CRP in the glyburide and
metformin groups was positively associated with changes in weight, but this was not the case
with rosiglitazone.
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C
-reactiveprotein(CRP)hasbeentra-
ditionally viewed as one of the
acute-phase reactants and is a sensi-
tive systemic marker of inﬂammation and
tissue damage. This acute-phase inﬂam-
matory protein is predominantly secreted
in hepatocytes, its release being regulated
by interleukin-6 and other inﬂammatory
cytokines (1). Other studies have shown
that extrahepatic sources of CRP produc-
tion from adipocytes could point to a
more systemic generation of CRP in the
body after stimulation by inﬂammatory
cytokines and more speciﬁcally, by the
adipokine, resistin (1).
Both population-based and prospec-
tive studies have demonstrated a clear as-
sociation between CRP and an increased
risk of cardiovascular disease (CVD) and
stroke(2).ThemagnitudeoftheCRPpre-
diction for future CVD events is similar to
that of other traditional CVD risk factors
(cholesterol, hypertension, and smoking
status) (2). CRP also may be a mediator of
atherosclerosis(1,3–6).However,thereis
no available evidence from clinical trials
that a reduction in CRP directly reduces
or prevents further CVD events.
The production of CRP by adipocytes
may partially explain why CRP levels are
elevated in patients with the metabolic
syndrome (1), in whom CVD risk is in-
creased. The strong association between
CRP and body adiposity has been ob-
served in both diabetic (7) and nondia-
betic subjects (8–11) and was only
moderately attenuated by adjustment of
insulin sensitivity. These results suggest
that obesity, insulin resistance, and the
metabolic syndrome are interconnected
in a proinﬂammatory state that may be
mediated by cytokines and subsequently
cause elevated levels of CRP. Elevated
CRP concentrations have been shown to
predict an increased risk of diabetes
(9,12,13).Therefore,CRPmayplayanac-
tive role in the causal relationship among
obesity, diabetes, and the high risk of fu-
ture CVD events. Statins (14) and weight
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els and improve other CVD risk factors,
also show beneﬁts in reducing CVD
events.
Glucose-lowering agents have differ-
ent effects on CRP, weight, insulin sensi-
tivity, and glycemic control in the
treatment of type 2 diabetes. The thiazo-
lidinediones (TZDs) rosiglitazone and
pioglitazone, insulin-sensitizing oral an-
tidiabetic agents, have been shown to be
effectiveinreducingCRPinseveralshort-
term (6 months) studies (18–21).
However, it is not clear whether the
weight gain associated with TZDs could
attenuate the effect on CRP reduction
over larger periods of time. In short-term
studies, metformin moderately decreases
CRP(16,18),increasesinsulinsensitivity,
and produces weight loss (16). The longer-
term relationships among the three com-
monly used oral antidiabetic agents
(TZDs, sulfonylureas, and metformin)
with CRP, insulin sensitivity, weight, and
glycemic control have not been investi-
gated previously.
A Diabetes Outcome Progression
Trial (ADOPT) provided the opportunity
toevaluatetheeffectsofmembersofthese
three classes of oral agents in a random-
ized, double-blind, controlled trial in-
volving 4,000 patients, treated for a
median time of 4 years (22,23). This
study compared the efﬁcacy and safety of
rosiglitazone, glyburide, and metformin
in drug-naive patients with newly diag-
nosed (3 years) type 2 diabetes. We
have previously reported the association
of CRP, obesity, and insulin resistance in
the baseline examination of the ADOPT
study (7). We discuss here a subgroup
analysis of ADOPT, in which we exam-
inedprospectivelythelong-termeffectsof
rosiglitazone, glyburide, and metformin
on CRP reduction and the relationship
among CRP, insulin sensitivity, weight,
and glycemic variables.
RESEARCH DESIGN AND
METHODS— ADOPT randomized
4,351 subjects from Europe and North
America who were drug-naive and in
whom type 2 diabetes was recently diag-
nosed. The study design of this interna-
tional, multicenter trial has been
described previously (23). A subgroup of
904 subjects from investigative centers in
the U.S. who had baseline CRP values
were included in this analysis. Of those
904 subjects, 304 were randomly as-
signed to rosiglitazone, 302 to glyburide,
and298tometformin.Atotalof783sub-
jects had both baseline and at least one
on-therapy value for CRP.
In brief, eligible subjects were aged
30–75yearsandhadafastingplasmaglu-
cose concentration between 7 and 10
mmol/ldespitedietandexerciseinterven-
tion. Eligible subjects were randomly as-
signed to double-blind treatment with a
1:1:1 ratio of the three glucose-lowering
medications.Initialdailydoseswere4mg
of rosiglitazone, 500 mg of metformin, or
2.5 mg of glyburide, and the dose was
titrated to the maximum effective daily
dose(4mgofrosiglitazonetwicedaily,1g
of metformin twice daily, and 7.5 mg of
glyburide twice daily). Uptitration of
study medication was required at each
visitwhenthefastingplasmaglucoselevel
was 7.8 mmol/l, whereas a reduction in
the dose of study medication was permit-
ted if adverse events occurred. The pri-
mary outcome was time to monotherapy
failure at the maximum-tolerated dose of
the study medication, deﬁned as fasting
plasma glucose 10 mmol/l (180 mg/dl)
on two successive occasions or by inde-
pendentadjudication.Thestudyprotocol
was reviewed and approved by institu-
tional review boards for each center, and
participants gave written, informed con-
sent before participating in the study.
Measurements and assays
Subjects had anthropometric measure-
ments (weight, height, and waist and hip
circumference)usingstandardizedproce-
dures across all study centers. Fasting
blood samples were drawn for measure-
ment of metabolic variables including
plasmaglucose,A1C,immunoreactivein-
sulin, and CRP. Metabolic assessments
were collected at baseline and every 6
monthsover4yearsoftreatment.Anthro-
pometric measurements were collected at
baseline and at yearly visits.
All assays were performed at a cen-
tral laboratory. Plasma glucose was
measured using a hexokinase method
(Olympus America, Melville, NY). A1C
was determined using the Variant A1C
assay (Bio-Rad, Hercules, CA). Serum
immunoreactive insulin was quantiﬁed
using a double-antibody radioimmuno-
assay (Linco Research, St. Louis, MO).
High-sensitivity CRP was measured by
ﬁxed-time nephelometry (reporting
range 0.2 mg/l to 10 g/l, coefﬁcient of
variation 7%; Dade Behring, Deer-
ﬁeld, IL). Insulin sensitivity was esti-
mated with homeostasis model assessment
of insulin resistance (HOMA2-IR) using
software available at http://www.dtu.ox.ac.
uk/homa.
Statistical methods
All statistical analyses were performed
with SAS (version 8.2; SAS Institute,
Cary, NC). All randomly assigned pa-
tients who received at least one dose of
study medication and had baseline CRP
and at least one postbaseline assessment
of CRP were included in the analysis. Al-
though the greatest reduction in CRP was
observed at 6 months, 12-month correla-
tionsarepresentedowingtoavailabilityof
data for all parameters evaluated at this
time point.
CRP and HOMA-IR values were log-
transformed to achieve a normal distribu-
tionbeforeanalysis.Resultsarepresented
as median (ﬁrst quartile, third quartile) at
baseline and the percent change from
baseline at each follow-up time. Changes
in CRP and weight over time were ana-
lyzed by a normal errors repeated-
measures model adjusted for baseline
value and sex (24). Partial correlation
analyses were performed using the Spear-
man method; the P value for differences
between groups was determined by the
Wilcoxon test. Other continuous data are
presented as mean  SEM. Two-sided
P  0.05 was considered statistically
signiﬁcant.
RESULTS— Of 904 participants, 706
remained at month 12 (239 in the rosigli-
tazone, 220 in the glyburide, and 247 in
the metformin group) and 413 at month
48 (153 in the rosiglitazone, 112 in the
glyburide, and 148 in the metformin
group). As reported previously, major
reasons for withdrawals were reaching a
monotherapy failure end point, adverse
events, and consent withdrawal (22).
Baseline anthropometric and meta-
bolic variables are listed in Table 1.
Women were more obese and insulin re-
sistantandhadmarkedlygreaterCRPlev-
els. However, baseline CRP values among
the three treatment groups were compa-
rable(geometricmean3.9mg/lintheros-
iglitazone group, 3.8 mg/l in the
glyburide group, and 3.7 mg/l in the met-
formin group).
Atbaseline,CRPwaspositivelycorre-
lated with BMI (r  0.44), waist circum-
ference(r0.40),waist-to-hipratio(r
0.11), and insulin resistance (r  0.30)
(all P  0.001). However, the correlation
between CRP and A1C (r  0.10, P 
0.004) was relatively weaker.
Percent changes in CRP over time by
Changes in CRP in ADOPT
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CRP declined over time in all three treat-
mentgroups,withthegreatestdecreasein
the rosiglitazone group, an intermediate
decrease in the metformin group, and the
leastdecreaseintheglyburidegroup.CRP
declined by 40% within 6 months of
initiationofrosiglitazonetreatment,com-
pared with 20% with glyburide and
metformin. At month 12, CRP was re-
duced from baseline by 42% in the ros-
iglitazone group, 10% in the glyburide
group, and 26% in the metformin group.
After 12 months, CRP continued to de-
crease gradually in all treatment groups.
After 48 months, the CRP reduction was
greater in the rosiglitazone group relative
to that in the glyburide group (47.6%,
P  0.001) and to that in the metformin
group (30.5%, P  0.004). Although the
absolute changes in CRP were greater in
womenthaninmen,thepercentchangesin
CRP over time were comparable between
sexes (Fig. 1B and C).
Weight gain was observed in the ros-
iglitazone and glyburide groups, whereas
weight loss was seen in the metformin
group (Fig. 2). At month 12, patients
treated with rosiglitazone or glyburide
gained an average of 3.6 and 2.8 kg, re-
spectively, whereas patients treated with
metformin lost 2.2 kg. At month 48, pa-
tients treated with rosiglitazone had sig-
niﬁcantly greater weight gain compared
with those treated with glyburide (3.8 kg,
P  0.0001) and metformin (8.5 kg, P 
0.0001). Changes from baseline in A1C
and HOMA-IR by treatment in this sub-
group were similar to those in the entire
study population (22). As reported previ-
ously (22), subjects treated with rosiglita-
zone demonstrated greater improvement
in HOMA-IR compared with those
treated with either glyburide or met-
formin. Rosiglitazone provided sustained
decreases in long-term A1C compared
withbothglyburideandmetformin;how-
ever, during the 1st year after commence-
ment of treatment, A1C reduction was
greatestwithglyburideandleastwithros-
iglitazone. Changes in waist, hip circum-
ference, and waist-to-hip ratio in each
treatment group observed in this cohort
were similar to those in the entire cohort
as well. Subjects treated with rosiglita-
zone and glyburide had an increase in
waist and hip circumference, whereas de-
creases in both waist and hip circumfer-
ence were observed in subjects treated
with metformin (22). The change in
waist-to-hip ratio among the treatment
groups was not different (22).
Therelationshipsbetweenthechange
in CRP from baseline to 1 year and the
change over the same time interval in an-
thropometric and metabolic variables are
presentedinTable2.CRPshowedaweak,
positive correlation with BMI in the gly-
buride and metformin groups and with
waist circumference in the glyburide
group. With rosiglitazone, CRP was not
correlatedwithglycemicoranthropomet-
ric variables. Of note, the correlation be-
tween change in CRP and change in BMI
withrosiglitazonetreatmenttrendedtobe
negative but was not signiﬁcant (r 
0.052, P  0.464).
CONCLUSIONS— Wehavedemon-
strated for the ﬁrst time a greater reduc-
tion in CRP in patients with newly
diagnosed type 2 diabetes treated for 4
years with rosiglitazone compared with
that in those treated with glyburide and
metformin. These observations occurred
in both men and women and are in line
with those from several small, short-term
studies in patients with type 2 diabetes
treatedwithrosiglitazone(19–21),trogli-
tazone (18), and pioglitazone (19,25).
Treatment with rosiglitazone or pioglita-
zone results in a rapid reduction in CRP
that occurs as early as 2 weeks after initi-
ationoftreatment(25,26),wellbeforethe
full effect of TZDs on glucose-lowering,
lipid proﬁle changes, and weight gain are
manifest. This temporal difference in
changes in CRP and metabolic markers
with rosiglitazone suggests that an im-
provement in adipose tissue metabolism
could be a prelude for other, later meta-
bolic changes. Unlike with rosiglitazone,
thereductioninCRPintheglyburideand
metformin groups was smaller and grad-
ual over time. Previous studies with met-
formin in subjects with type 2 diabetes
(18) and impaired glucose tolerance (16)
have shown similar results—a modest re-
duction in CRP levels.
In previous cross-sectional reports
CRP was positively associated with obe-
sity in both diabetic and nondiabetic pa-
tients (7–11). The current analysis using
change in CRP and BMI from baseline to
12 months shows that rosiglitazone treat-
ment disassociates the relationship be-
tween CRP and BMI; in contrast, the
relationship is positive in both the gly-
buride and metformin groups as has
been shown in observational studies
(7,8,10,11). Subjects treated with rosigli-
tazoneexperiencedweightgainovertime;
however, this increase in weight occurred
graduallyandwasnotaccompaniedbyan
increase in CRP. This result may possibly
be due to the increase in subcutaneous
adiposetissueandﬂuidretentionthatcan
be attributed to rosiglitazone. The corre-
lation between CRP and waist circumfer-
ence or waist-to-hip ratio followed a
similar pattern.
There was a strong positive correla-
tion between CRP and insulin resistance
at baseline in all three groups. However,
the changes from baseline to 1 year in
these parameters in the rosiglitazone
group were not signiﬁcant. This ﬁnding
was unexpected, because changes in CRP
and insulin resistance over time in the
rosiglitazonegroupwouldhavebeenpre-
dictedtobepositivelycorrelated.Thisob-
servation suggests that rosiglitazone
regulates CRP and insulin resistance
through different mechanisms, which
have not yet been elucidated.
A weak correlation between CRP and
A1C was observed in the cohort at base-
Table1—MetabolicandanthropometricvariablesinNorthAmericansubjectswithCRPvalue
at baseline
Men Women Total
n 467 437 904
CRP (mg/l)* 2.5, (1.3, 5.1) 6.2, (2.9, 10.2)† 4.0, (1.9, 8.4)
HOMA-IR (%)* 3.1, (2.2, 4.5) 3.8, (2.5, 5.3)† 3.5, (2.3, 5.0)
A1C (%) 7.5  0.99 7.4  0.94 7.5  0.97
Age (years) 55.9  10.16 54.5  10.67‡ 55.2  10.42
Weight (kg) 100.7  20.7 93.3  20.9† 97.1  21.1
BMI (kg/m
2) 32.1  5.96 35.2  7.59† 33.6  6.97
Waist circumference (cm)§ 109.0  15.34 105.8  16.17‡ 107.4  15.82
Waist-to-hip ratio 0.97  0.061 0.90  0.079† 0.94  0.080
Data are means  SD unless indicated otherwise. All data are from subjects who had a baseline CRP value.
*Data were log-transformed and are median (25th and 75th quartiles). Wilcoxon test indicated signiﬁcant
differences between men and women (†P  0.0001; ‡P  0.01). §For waist circumference the number of
women was 436, giving a total of 903.
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diabetic (27) and elderly type 2 diabetic
subjects (28) and probably reﬂects sub-
clinical microinﬂammation of the vascu-
lature associated with increased blood
glucose. However, in this analysis, im-
provement in A1C after initiation of glu-
cose-lowering therapy did not correlate
with the changes in CRP with all three
treatments. In keeping with glucose not
being an important determinant of CRP,
in ADOPT, over the duration of the study
A1Ctrendedupwardwithbothglyburide
and metformin, with a slope of 0.24 and
0.14% per year, respectively (22),
whereas CRP values trended downward
over time in both groups. This observa-
tion also suggests that different pharma-
cological agents affect A1C and CRP
through different pathways.
Recently, evidence from large popu-
lation-based and prospective studies pro-
videdsupportthatsystemicinﬂammation
biomarkers, such as CRP, may be inte-
grated into the algorithm when the risk of
future CVD events (2) is calculated. Some
investigators have challenged the impor-
tance of CRP in prediction of CHD (29)
usinganareaunderthereceiveroperating
curve approach, whereas others have
pointed out limitations of the area under
the receiver operating curve approach
(30).Furthermore,therearefewdataspe-
ciﬁcallyaddressingtheroleofCRPinpre-
dictingfutureCVDeventsinpatientswith
type 2 diabetes. CRP might possibly be
checked periodically along with other
CVD risk factors in patients at higher risk
of developing cardiovascular disease but
probably should not be used at this time
in clinical practice to follow the effect of
glycemic interventions.
Thediscrepancybetweenthepossible
beneﬁt in surrogate markers (19–21) and
even in atherosclerosis (31) and CVD
events with TZDs is not well understood.
In a recent meta-analysis of rosiglitazone
(32), an increased risk of myocardial in-
farction and CVD deaths was observed in
combined small, short-term trials. How-
ever,thisincreasedriskinCVDdeathwas
notobservedinlarge,long-termtrials.Al-
though ADOPT (22) had a low rate of
CVD events, the interim analysis from the
Rosiglitazone Evaluated for Cardiovascu-
lar Outcomes Study (RECORD) (33) (vs.
metformin or sulfonylurea) was based on
adjudicated events and showed statisti-
cally insigniﬁcant increases in myocardial
infarction and statistically insigniﬁcant
decreases in CVD death. In PROspective
pioglitAzone Clinical Trial In macroVas-
Figure 1—Percent (A–C) changes from baseline in CRP in different treatment groups. Data are
percent change  SEM. Rosiglitazone is in blue, metformin is in green, and glyburide is in red.
Dataareshownforthewholecohort(A),women(B),andmen(C)overtimeindifferenttreatment
groups.
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tazone improved glycemic control and
lipoproteins relative to placebo, but these
beneﬁts did not translate to expected sig-
niﬁcant decreases in CVD outcomes as
deﬁned for the primary end point (al-
though a secondary cardiovascular end
point was signiﬁcantly reduced with pio-
glitazone). The CRP concentration was
notassessedinPROACTIVE.Severalpos-
sibilities for the discrepancy between the
lack of positive effects on CVD and the
beneﬁcialeffectsonsurrogatemarkersex-
ist, including chance due to low power
and short duration of many studies; alter-
natively, surrogates such as CRP or mea-
sures of atherosclerosis may not be
informativeforTZDs,aswasthecasewith
the HDL-raising medication torcetrapib
(35,36). Another possibility is that TZDs
may have other effects that are not under-
stood and could potentially counterbal-
ancetheeffectsofreducinginﬂammation.
Any beneﬁts of CRP reduction by TZDs
may only be adequately evaluated in a
long-term study for CVD outcomes in
whichvariablessuchasglucoseandlipids
are well controlled with therapy. Thus, at
this time, we believe the long-term effect
ofTZDsshouldbeviewedlargelyfortheir
improvement in adipose tissue metabo-
lism, modulation of endocrine function-
ality of adipocytes, and durability of
glycemic control, therefore partially re-
ducing the long-term burden for athero-
genesis in patients with type 2 diabetes.
In summary, we have reported the
long-term differential effects of three
commonly used oral antidiabetes agents
on the systemic inﬂammatory biomarker
CRP in subjects with recently diagnosed
type 2 diabetes. Treatment with rosiglita-
zone was associated with a rapid and du-
rable reduction in CRP independent of
changes in insulin sensitivity, A1C, and
weight gain. Treatment with glyburide
and metformin was associated with a
moderate and gradual reduction in CRP
and was partly associated with changes in
weight but independent of glycemic con-
trol and insulin sensitivity. The possible
value of CRP reduction by glucose-
lowering therapy for future CVD events
needs to be considered with other CVD
risk factors in patients with type 2 diabe-
tes. This issue needs to be evaluated in
larger, longer-term clinical trials with ad-
equate samples and adjudication of car-
diovascular events.
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